Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phoenix Trial of AMX0035 in ALS
NCT05021536Phase 3Active, not recruiting
- Sponsor
- Amylyx Pharmaceuticals
- Start
- Oct 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of sodium phenylbutyrate in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Amylyx Pharmaceuticals. Primary endpoint: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised Slope Change at 48 weeks. Started Oct 2021; status: active, not recruiting.
02
Drugs
sodium phenylbutyrate
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05021536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05021536.